This document provides an overview of Allon Therapeutics Inc., a biopharmaceutical company developing novel neuroprotective peptides. Their lead product, davunetide, has demonstrated human proof of concept in Phase 2 trials for Alzheimer's disease and is currently in an international Phase 2/3 pivotal trial for Progressive Supranuclear Palsy. Allon has a portfolio of neuroprotective peptides targeting various conditions and is pursuing orphan drug approval and commercialization while advancing their second generation products.